As a remainder FY16 was marked by revenues at €540m, down 6% yoy, an expected decline following the disposal of Gecimed, and the lack of immediate EPS accretive acquisitions. Revenues also came in flat on an organic basis, on the still lagging indexation and negative reversions from rent renegotiations done in 2015. EPS at €5.52 declined by 1.7% yoy, and the dividend was increased by 4% to stand at €5.20/share. The financial position remained strong with an LTV now at 29.4% whi
29 Mar 2017
2018, a strong delivery year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2018, a strong delivery year
Gecina SA (GFC:WBO) | 0 0 2.8% | Mkt Cap: 11,480m
- Published:
29 Mar 2017 -
Author:
Alda Kule Dale -
Pages:
2
As a remainder FY16 was marked by revenues at €540m, down 6% yoy, an expected decline following the disposal of Gecimed, and the lack of immediate EPS accretive acquisitions. Revenues also came in flat on an organic basis, on the still lagging indexation and negative reversions from rent renegotiations done in 2015. EPS at €5.52 declined by 1.7% yoy, and the dividend was increased by 4% to stand at €5.20/share. The financial position remained strong with an LTV now at 29.4% whi